Information de reference pour ce titreAccession Number: | 01268358-201207000-00010.
|
Author: | Sacksteder, Katherine A 1; Protopopova, Marina 1; Barry, Clifton E 2; Andries, Koen 3; Nacy, Carol A *,1,4
|
Institution: | (1)Sequella, Inc., Rockville, MD, USA (2)Tuberculosis Research Section, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, USA (3)Antimicrobial Research, Janssen Infectious Diseases, Beerse, Belgium (4)Sequella, Inc., Rockville, MD, USA. E-mail: [email protected]
|
Title: | Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.[Miscellaneous Article]
|
Source: | Future Microbiology. 7(7):823-837, July 2012.
|
Abstract: | Existing drugs have limited efficacy against the rising threat of drug-resistant TB, have significant side effects, and must be given in combinations of four to six drugs for at least 6 months for drug-sensitive TB and up to 24 months for drug-resistant TB. The long treatment duration has led to increased patient noncompliance with therapy. This, in turn, drives the development of additional drug resistance in a spiral that has resulted in some forms of TB being currently untreatable by existing drugs. New antitubercular drugs in development, particularly those with mechanisms of action that are different from existing first- and second-line TB drugs, are anticipated to be effective against both drug-sensitive and drug-resistant TB. SQ109 is a new TB drug candidate with a novel mechanism of action that was safe and well tolerated in Phase I and early Phase II clinical trials. We describe herein the identification, development and characterization of SQ109 as a promising new antitubercular drug.
(C) 2012Future Medicine, Ltd.
|
Author Keywords: | antitubercular agent; clinical trial; drug discovery; drug resistance; MDR-TB; pharmacology; tuberculosis; XDR-TB.
|
References: | 1 Stevenson CR, Forouhi NG, Roglic G et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 7, 234 (2007).
2 Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163(9), 1009-1021 (2003).
3 Nolan CM. Beyond directly observed therapy for tuberculosis. Chest 111(5), 1151-1153 (1997).
4 Castelnuovo B. A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in sub Saharan Africa. Afr. Health Sci. 10(4), 320-324 (2010).
5 Vieira AA, Ribeiro SA. Compliance with tuberculosis treatment after the implementation of the directly observed treatment, short-course strategy in the city of Carapicuiba, Brazil. J. Bras. Pneumol. 37(2), 223-231 (2011).
6 Small PM, Hopewell PC, Singh SP et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N. Engl. J. Med. 330(24), 1703-1709 (1994).
7 O'Brien JK, Sandman LA, Kreiswirth BN, Rom WN, Schluger NW. DNA fingerprints from Mycobacterium tuberculosis isolates of patients confined for therapy noncompliance show frequent clustering. Chest 112(2), 387-392 (1997).
8 Coker RJ. Public health impact of detention of individuals with tuberculosis: systematic literature review. Public Health 117(4), 281-287 (2003).
9 Weis SE, Slocum PC, Blais FX et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N. Engl. J. Med. 330(17), 1179-1184 (1994).
10 Orenstein EW, Basu S, Shah NS et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis. 9(3), 153-161 (2009).
11 Zumla A, Abubakar I, Raviglione M et al. Drug-resistant tuberculosis - current dilemmas, unanswered questions, challenges, and priority needs. J. Infect. Dis. 205(Suppl. 2), S228-S240 (2012).
12 Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375(9728), 1830-1843 (2010).
13 Sotgiu G, Ferrara G, Matteelli A et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur. Respir. J. 33(4), 871-881 (2009).
14 Friedland G. Tuberculosis, drug resistance, and HIV/AIDS: a triple threat. Curr. Infect. Dis. Rep. 9(3), 252-261 (2007).
15 Wells CD, Cegielski JP, Nelson LJ et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J. Infect. Dis. 196(Suppl. 1), S86-S107 (2007).
16 Farley JE, Ram M, Pan W et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One 6(7), e20436 (2011).
17 Ginsberg AM. Drugs in development for tuberculosis. Drugs 70(17), 2201-2214 (2010).
18 Rivers EC, Mancera RL. New anti-tuberculosis drugs with novel mechanisms of action. Curr. Med. Chem. 15(19), 1956-1967 (2008).
19 Lalloo UG, Ambaram A. New antituberculous drugs in development. Curr. HIV/AIDS Rep. 7(3), 143-151 (2010).
20 Dover LG, Coxon GD. Current status and research strategies in tuberculosis drug development. J. Med. Chem. 54(18), 6157-6165 (2011).
21 Sala C, Hartkoorn RC. Tuberculosis drugs: new candidates and how to find more. Future Microbiol. 6(6), 617-633 (2011).
22 Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52(8), 2831-2835 (2008).
23 Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360(23), 2397-2405 (2009).
24 Tahlan K, Wilson R, Kastrinsky DB et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56(4), 1797-1809 (2012). [black small square] Identification of a novel target of SQ109.
25 Grzegorzewicz AE, Pham H, Gundi VA et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8(4), 334-341 (2012).
26 Leach KL, Brickner SJ, Noe MC, Miller PF. Linezolid, the first oxazolidinone antibacterial agent. Ann. NY Acad. Sci. 1222, 49-54 (2011).
27 Villar M, Sotgiu G, D'Ambrosio L et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur. Respir. J. 38(3), 730-733 (2011).
28 Migliori GB, Eker B, Richardson MD et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J. 34(2), 387-393 (2009).
29 Von Der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - a report of ten cases. J. Infect. 52(2), 92-96 (2006).
30 Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis. 50(1), 49-55 (2010).
31 Dietze R, Hadad DJ, McGee B et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 178(11), 1180-1185 (2008).
32 Lofmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin. Infect. Dis. 50(Suppl. 1), S16-S23 (2010).
33 Brooks JV, Furney SK, Orme IM. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 43(5), 1285-1288 (1999).
34 Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13(11), 908-914 (1994).
35 Paramasivan CN, Kubendiran G, Herbert D. Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. Indian J. Med. Res. 108, 115-119 (1998).
36 Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J. Infect. Dis. 198(2), 275-283 (2008).
37 Dhillon J, Allen BW, Hu YM, Coates AR, Mitchison DA. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuberc. Lung Dis. 2(9), 736-742 (1998).
38 Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46(4), 1022-1025 (2002).
39 Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis. 15(7), 949-954 (2011).
40 Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 54(8), 3402-3407 (2010).
41 Barbachyn MR, Hutchinson DK, Brickner SJ et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem. 39(3), 680-685 (1996).
42 Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43(5), 1189-1191 (1999).
43 Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann. NY Acad. Sci. 1241(1), 48-70 (2011).
44 Wallis RS, Jakubiec W, Kumar V et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother. 55(2), 567-574 (2011).
45 Wallis RS, Jakubiec WM, Kumar V et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202(5), 745-751 (2010).
46 Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE 3rd. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J. Comb. Chem. 5(2), 172-187 (2003).
47 Desimoni G. Preliminary observations of ethambutol in pulmonary tuberculosis. Ann. NY Acad. Sci. 135(2), 846-848 (1966).
48 Donomae I, Yamamoto K. Clinical evaluation of ethambutol in pulmonary tuberculosis. Ann. NY Acad. Sci. 135(2), 849-881 (1966).
49 Zhu M, Burman WJ, Starke JR et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int. J. Tuberc. Lung Dis. 8(11), 1360-1367 (2004).
50 Alland D, Steyn AJ, Weisbrod T, Aldrich K, Jacobs WR Jr. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J. Bacteriol. 182(7), 1802-1811 (2000).
51 Bogatcheva E, Hanrahan C, Nikonenko B et al. Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorg. Med. Chem. Lett. 21(18), 5353-5357 (2011).
52 Bogatcheva E, Hanrahan C, Nikonenko B et al. Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J. Med. Chem. 49(11), 3045-3048 (2006).
53 Bogatcheva E, Hanrahan C, Chen P et al. Discovery of dipiperidines as new antitubercular agents. Bioorg. Med. Chem. Lett. 20(1), 201-205 (2010).
54 Protopopova M, Hanrahan C, Nikonenko B et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother. 56(5), 968-974 (2005). [black small square][black small square] Demonstration of in vitro and in vivo activity of TB drug candidate SQ109.
55 Jia L, Tomaszewski JE, Noker PE, Gorman GS, Glaze E, Protopopova M. Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization. J. Pharm. Biomed. Anal. 37(4), 793-799 (2005).
56 Nikonenko BV, Samala R, Einck L, Nacy CA. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48(12), 4550-4555 (2004).
57 Onajole OK, Sosibo S, Govender P et al. Novel linear diamine disubstituted polycyclic 'cage' derivatives as potential antimycobacterial candidates. Chem. Biol. Drug Des. 78(6), 1022-1030 (2011).
58 Onajole OK, Govender P, Van Helden PD et al. Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. Eur. J. Med. Chem. 45(5), 2075-2079 (2010).
59 Meng Q, Luo H, Chen Y, Wang T, Yao Q. Synthesis of novel [1,2]-diamines with antituberculosis activity. Bioorg. Med. Chem. Lett. 19(18), 5372-5375 (2009).
60 Jia L, Tomaszewski JE, Hanrahan C et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144(1), 80-87 (2005). [black small square] Demonstrates that SQ109 accumulates in the lung, a target organ for TB treatment.
61 Armstrong JA, Hart PD. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 134(3 Pt 1), 713-740 (1971).
62 Yendapally R, Lee RE. Design, synthesis, and evaluation of novel ethambutol analogues. Bioorg. Med. Chem. Lett. 18(5), 1607-1611 (2008).
63 Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. Int. J. Tuberc. Lung Dis. 10(12), 1318-1330 (2006).
64 Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE 3rd. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279(38), 40174-40184 (2004).
65 Jia L, Coward L, Gorman GS, Noker PE, Tomaszewski JE. Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N[spacing acute]-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv. J. Pharmacol. Exp. Ther. 315(2), 905-911 (2005).
66 Goude R, Amin AG, Chatterjee D, Parish T. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53(10), 4138-4146 (2009).
67 Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 33(9), 1493-1499 (1989).
68 Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother. 58(2), 332-337 (2006).
69 Van Deun A, Maug AK, Salim MA et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182(5), 684-692 (2010).
70 Reddy VM, O'Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. 43(5), 615-623 (1999).
71 Langdon G, Wilkins JJ, Smith PJ, McIlleron H. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 8(7), 862-867 (2004).
72 Reddy VM, Dubuisson T, Einck L et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J. Antimicrob. Chemother. 67(5), 1163-1166 (2012). [black small square] Demonstration of synergy between two investigational drugs with novel mechanisms of action.
73 Wallis RS, Jakubiec W, Mitton-Fry M et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 7(1), e30479 (2012). [black small square][black small square] Evaluation of multiple regimens found that the most active was a combination of investigational drugs with entirely new mechanisms of action, which could be used to treat both drug-sensitive and drug-resistant TB.
74 Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54(7), 2840-2846 (2010). [black small square] Demonstration of synergy between two investigational drugs with novel mechanisms of action.
75 Meng Q, Luo H, Liu Y, Li W, Zhang W, Yao Q. Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents. Bioorg. Med. Chem. Lett. 19(10), 2808-2810 (2009).
76 Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob. Agents Chemother. 51(4), 1563-1565 (2007).
77 Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, Tomaszewski JE. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br. J. Pharmacol. 147(5), 476-485 (2006).
78 Sreevatsan S, Stockbauer KE, Pan X et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob. Agents Chemother. 41(8), 1677-1681 (1997).
79 Plinke C, Cox HS, Zarkua N et al. embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation. J. Antimicrob. Chemother. 65(7), 1359-1367 (2010).
80 Belanger AE, Besra GS, Ford ME et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl Acad. Sci. USA 93(21), 11919-11924 (1996).
101 WHO. Global Tuberculosis Control 2011. (2011). www.who.int/tb/publications/global_report/en
102 Linezolid to Treat Extensively-Drug Resistant Tuberculosis. http://clinicaltrials.gov/ct2/sh...- ouverture dans une nouvelle fenêtre
103 Metronidazole for Pulmonary Tuberculosis (South Korea). http://clinicaltrials.gov/ct2/sh...- ouverture dans une nouvelle fenêtre
104 US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research (CDER). New Guidance for Industry: Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination. (December 2010). www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm237264.htm
|
Language: | English.
|
Document Type: | Drug Evaluation.
|
Journal Subset: | Life & Biomedical Sciences.
|
ISSN: | 1746-0913
|
NLM Journal Code: | 101278120
|
DOI Number: | https://dx.doi.org/10.2217/fmb.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|